tourmaline-mm4: oral ixazomib maintenance for myeloma
Published 4 years ago • 247 plays • Length 4:47Download video MP4
Download video MP3
Similar videos
-
2:54
tourmaline-mm4: oral ixazomib maintenance for myeloma
-
4:19
tourmaline-mm3 and 4: ixazomib as maintenance therapy in myeloma patients
-
9:57
measurable residual disease evaluation during ixazomib maintenance in ndmm: tourmaline-mm3 and -mm4
-
1:18
the talisman study: prophylactic treatment for talquetamab-related oral toxicity in myeloma
-
2:07
key findings of the pooled analysis of the tourmaline-mm3 and mm4 trials
-
2:36
what does the tourmaline-mm2 study tell us about the use of ixazomib in multiple myeloma?
-
2:53
mrd evaluation during ixazomib maintenance in myeloma
-
6:23
how long will i live with multiple myeloma, and is there a cure? #myeloma
-
9:41
the i4mds consortium and immune monitoring in mds
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
2:21
overview of the tourmaline-mm1 study in relapsed/refractory multiple myeloma
-
1:45
latest updates on maintenance therapy in myeloma
-
1:12
insights into majestec-4: assessing the role of teclistamab as maintenance in patients with myeloma
-
1:22
long-term follow-up results of tourmaline-mm2: ird vs pbo-rd in multiple myeloma
-
3:03
prognostic importance of mrd: results of tourmaline-mm4 trial for ndmm
-
3:01
treatment approaches for asct-eligible myeloma patients in the frontline
-
1:30
real-world treatment patterns in third-line therapy for r/r myeloma
-
1:33
tourmaline-mm3: undetectable mrd as an endpoint for maintenance therapy
-
4:19
final analysis of uvea-ixa study of ixazomib in r/r myeloma
-
4:48
overview of the final analysis of the phase iii tourmaline-mm1 trial
-
1:00
quadruplet induction therapy in newly diagnosed high-risk myeloma